enVVeno Medical Corporation (NVNO)
NASDAQ: NVNO · Real-Time Price · USD
0.7814
-0.0046 (-0.59%)
At close: Sep 12, 2025, 4:00 PM EDT
0.7920
+0.0106 (1.36%)
Pre-market: Sep 15, 2025, 8:00 AM EDT
enVVeno Medical Employees
enVVeno Medical had 37 employees as of December 31, 2024. The number of employees increased by 6 or 19.35% compared to the previous year.
Employees
37
Change (1Y)
6
Growth (1Y)
19.35%
Revenue / Employee
n/a
Profits / Employee
-$623,459
Market Cap
15.04M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 37 | 6 | 19.35% |
| Dec 31, 2023 | 31 | 1 | 3.33% |
| Dec 31, 2022 | 30 | 6 | 25.00% |
| Dec 31, 2021 | 24 | 5 | 26.32% |
| Dec 31, 2020 | 19 | 7 | 58.33% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NVNO News
- 26 days ago - enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R) - Accesswire
- 4 weeks ago - enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - Accesswire
- 5 weeks ago - Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency - Accesswire
- 5 weeks ago - enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company - Accesswire
- 6 weeks ago - enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Accesswire
- 7 weeks ago - enVVeno Medical Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference - Accesswire
- 3 months ago - Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting - Accesswire
- 4 months ago - enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer - Accesswire